avsola.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * Sitemap: | ||
Meta Tags
| Title | AVSOLA®(infliximab-axxq) a Remicade® |
| Description | THE AMGEN EXPERIENCE YOU CAN Learn more about AVSOLA® (infliximab-axxq), a biosimilar FDA approved for the same indications as Remicade®. See the full Important Safety Info and PI, including Boxed |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 52.25.187.138 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
avsola.com Valuation
|
US$24,779,529
Last updated: 2023-05-03 14:54:36
avsola.com has Semrush global rank of 427,139. avsola.com has an estimated worth of US$ 24,779,529, based on its estimated Ads revenue. avsola.com receives approximately 2,859,177 unique visitors each day. Its web server is located in United States, with IP address 52.25.187.138. According to SiteAdvisor, avsola.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$24,779,529 |
| Daily Ads Revenue | US$22,874 |
| Monthly Ads Revenue | US$686,203 |
| Yearly Ads Revenue | US$8,234,428 |
| Daily Unique Visitors | 190,612 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| avsola.com. | A | 299 | IP: 52.25.187.138 |
| avsola.com. | A | 299 | IP: 52.43.121.28 |
| avsola.com. | NS | 86400 | NS Record: ns-1803.awsdns-33.co.uk. |
| avsola.com. | NS | 86400 | NS Record: ns-428.awsdns-53.com. |
| avsola.com. | NS | 86400 | NS Record: ns-871.awsdns-44.net. |
| avsola.com. | NS | 86400 | NS Record: ns-1057.awsdns-04.org. |
HtmlToTextCheckTime:2023-05-03 14:54:36
| Indications AVSOLA® is indicated for: Crohn’s Disease: Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an ... Read more AVSOLA® is indicated for: Crohn’s Disease: Reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. AVSOLA® is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease. Pediatric Crohn’s Disease: Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age or older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Ulcerative Colitis: Reducing signs and symptoms, inducing and maintaining |
HTTP Headers
HTTP/1.1 403 Forbidden Server: awselb/2.0 Date: Mon, 25 Oct 2021 20:57:10 GMT Content-Type: text/html Content-Length: 118 Connection: keep-alive |
avsola.com Whois Information
Domain Name: AVSOLA.COM Registry Domain ID: 2063919624_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.markmonitor.com Registrar URL: http://www.markmonitor.com Updated Date: 2020-09-03T09:14:22Z Creation Date: 2016-10-05T18:23:17Z Registry Expiry Date: 2022-10-05T18:23:17Z Registrar: MarkMonitor Inc. Registrar IANA ID: 292 Registrar Abuse Contact Email: abusecomplaints@markmonitor.com Registrar Abuse Contact Phone: +1.2083895740 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS-1057.AWSDNS-04.ORG Name Server: NS-1803.AWSDNS-33.CO.UK Name Server: NS-428.AWSDNS-53.COM Name Server: NS-871.AWSDNS-44.NET DNSSEC: unsigned >>> Last update of whois database: 2021-09-13T23:03:35Z <<< |